172 related articles for article (PubMed ID: 17948965)
1. Upregulation of MICA on high-grade invasive operable breast carcinoma.
Madjd Z; Spendlove I; Moss R; Bevin S; Pinder SE; Watson NF; Ellis I; Durrant LG
Cancer Immun; 2007 Oct; 7():17. PubMed ID: 17948965
[TBL] [Abstract][Full Text] [Related]
2. CD56+ immune cell infiltration and MICA are decreased in breast lobules with fibrocystic changes.
Kerekes D; Visscher DW; Hoskin TL; Radisky DC; Brahmbhatt RD; Pena A; Frost MH; Arshad M; Stallings-Mann M; Winham SJ; Murphy L; Denison L; Carter JM; Knutson KL; Degnim AC
Breast Cancer Res Treat; 2018 Feb; 167(3):649-658. PubMed ID: 29090365
[TBL] [Abstract][Full Text] [Related]
3. Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast.
Tsutsui S; Inoue H; Yasuda K; Suzuki K; Higashi H; Era S; Mori M
Oncology; 2005; 68(4-6):398-404. PubMed ID: 16020969
[TBL] [Abstract][Full Text] [Related]
4. Elevated Hu-Antigen Receptor (HuR) Expression is Associated with Tumor Aggressiveness and Poor Prognosis but not with COX-2 Expression in Invasive Breast Carcinoma Patients.
Giaginis C; Sampani A; Kotta-Loizou I; Giannopoulou I; Danas E; Politi E; Tsourouflis G; Kouraklis G; Patsouris E; Keramopoulos A; Nakopoulou L; Theocharis S
Pathol Oncol Res; 2018 Jul; 24(3):631-640. PubMed ID: 28808873
[TBL] [Abstract][Full Text] [Related]
5. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17.
Chitadze G; Lettau M; Bhat J; Wesch D; Steinle A; Fürst D; Mytilineos J; Kalthoff H; Janssen O; Oberg HH; Kabelitz D
Int J Cancer; 2013 Oct; 133(7):1557-66. PubMed ID: 23526433
[TBL] [Abstract][Full Text] [Related]
6. Granulin-epithelin precursor renders hepatocellular carcinoma cells resistant to natural killer cytotoxicity.
Cheung PF; Yip CW; Wong NC; Fong DY; Ng LW; Wan AM; Wong CK; Cheung TT; Ng IO; Poon RT; Fan ST; Cheung ST
Cancer Immunol Res; 2014 Dec; 2(12):1209-19. PubMed ID: 25315249
[TBL] [Abstract][Full Text] [Related]
7. Correlation between histological grade and c-erbB2 oncoprotein overexpression in infiltrating ductal carcinoma of breast.
Looi LM; Cheah PL; Yap SF
Malays J Pathol; 1997 Jun; 19(1):35-9. PubMed ID: 10879240
[TBL] [Abstract][Full Text] [Related]
8. CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy.
Han Y; Sun F; Zhang X; Wang T; Jiang J; Cai J; Gao Q; Hezam K; Liu Y; Xie J; Wang M; Zhang J
J Cancer Res Clin Oncol; 2019 May; 145(5):1179-1190. PubMed ID: 30778749
[TBL] [Abstract][Full Text] [Related]
9. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.
Pende D; Rivera P; Marcenaro S; Chang CC; Biassoni R; Conte R; Kubin M; Cosman D; Ferrone S; Moretta L; Moretta A
Cancer Res; 2002 Nov; 62(21):6178-86. PubMed ID: 12414645
[TBL] [Abstract][Full Text] [Related]
10. Expression of MAGE tumour-associated antigens is inversely correlated with tumour differentiation in invasive ductal breast cancers: an immunohistochemical study.
Kavalar R; Sarcevic B; Spagnoli GC; Separovic V; Samija M; Terracciano L; Heberer M; Juretic A
Virchows Arch; 2001 Aug; 439(2):127-31. PubMed ID: 11561752
[TBL] [Abstract][Full Text] [Related]
11. HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines.
Okita R; Mougiakakos D; Ando T; Mao Y; Sarhan D; Wennerberg E; Seliger B; Lundqvist A; Mimura K; Kiessling R
J Immunol; 2012 Mar; 188(5):2136-45. PubMed ID: 22301547
[TBL] [Abstract][Full Text] [Related]
12. Expression of CD 133 in Invasive Ductal Carcinoma of Breast.
Utnal PA; A H; Pn S; Gn M
Asian Pac J Cancer Prev; 2020 Oct; 21(10):3055-3059. PubMed ID: 33112567
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of MICA and MICB Shedding Elicits NK-Cell-Mediated Immunity against Tumors Resistant to Cytotoxic T Cells.
Ferrari de Andrade L; Kumar S; Luoma AM; Ito Y; Alves da Silva PH; Pan D; Pyrdol JW; Yoon CH; Wucherpfennig KW
Cancer Immunol Res; 2020 Jun; 8(6):769-780. PubMed ID: 32209637
[TBL] [Abstract][Full Text] [Related]
14. Is the tumor infiltrating natural killer cell (NK-TILs) count in infiltrating ductal carcinoma of breast prognostically significant?
Rathore AS; Goel MM; Makker A; Kumar S; Srivastava AN
Asian Pac J Cancer Prev; 2014; 15(8):3757-61. PubMed ID: 24870789
[TBL] [Abstract][Full Text] [Related]
15. Elevated Interleukin-13 Receptor Alpha 1 Expression in Tumor Cells Is Associated with Poor Prognosis in Patients with Invasive Breast Cancer.
Park MH; Kwon HJ; Kim JR; Lee B; Lee SJ; Bae YK
Ann Surg Oncol; 2017 Nov; 24(12):3780-3787. PubMed ID: 28634667
[TBL] [Abstract][Full Text] [Related]
16. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.
Yan J; Liu XL; Han LZ; Xiao G; Li NL; Deng YN; Yin LC; Ling LJ; Yu XY; Tan CL; Huang XP; Liu LX
Asian Pac J Cancer Prev; 2015; 16(2):823-9. PubMed ID: 25684532
[TBL] [Abstract][Full Text] [Related]
17. High survivin mRNA expression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein level.
Xu C; Yamamoto-Ibusuki M; Yamamoto Y; Yamamoto S; Fujiwara S; Murakami K; Okumura Y; Yamaguchi L; Fujiki Y; Iwase H
Breast Cancer; 2014 Jul; 21(4):482-90. PubMed ID: 22968628
[TBL] [Abstract][Full Text] [Related]
18. MICA immune complex formed with alpha 3 domain-specific antibody activates human NK cells in a Fc-dependent manner.
Du C; Bevers J; Cook R; Lombana TN; Rajasekaran K; Matsumoto M; Spiess C; Kim JM; Ye Z
J Immunother Cancer; 2019 Aug; 7(1):207. PubMed ID: 31387641
[TBL] [Abstract][Full Text] [Related]
19. Interaction of monocytes with NK cells upon Toll-like receptor-induced expression of the NKG2D ligand MICA.
Kloss M; Decker P; Baltz KM; Baessler T; Jung G; Rammensee HG; Steinle A; Krusch M; Salih HR
J Immunol; 2008 Nov; 181(10):6711-9. PubMed ID: 18981088
[TBL] [Abstract][Full Text] [Related]
20. Total loss of MHC class I is an independent indicator of good prognosis in breast cancer.
Madjd Z; Spendlove I; Pinder SE; Ellis IO; Durrant LG
Int J Cancer; 2005 Nov; 117(2):248-55. PubMed ID: 15900607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
